Increased cortical bone mineralization in imatinib treated patients with chronic myelogenous leukemia.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

17 citing papers in PubMed.

1. Changes in bone metabolic parameters in children with chronic myeloid leukemia on imatinib treatment.Medical science monitor : international medical journal of experimental and clinical research · 2012
   Trial
2. Effect of the tyrosine kinase inhibitors on the growth in children with Philadelphia chromosome-positive acute lymphoblastic leukemia: a case-control study.The Lancet regional health. Western Pacific · 2023
   Article
3. Bone Metabolism Effects of Medical Therapy in Advanced Renal Cell Carcinoma.Cancers · 2023
   Review
4. Effects of imatinib and nilotinib on the whole transcriptome of cultured murine osteoblasts.Molecular medicine reports · 2016
   Article
5. Tyrosine Kinase Inhibitors Regulate OPG through Inhibition of PDGFRβ.PloS one · 2016
   Article
6. Impact of long-term exposure to the tyrosine kinase inhibitor imatinib on the skeleton of growing rats.PloS one · 2015
   Article
7. Use of imatinib in the prevention of heterotopic ossification.HSS journal : the musculoskeletal journal of Hospital for Special Surgery · 2013
   Article
8. Clinical review: kinase inhibitors: adverse effects related to the endocrine system.The Journal of clinical endocrinology and metabolism · 2013
   Review
9. Bone metabolism, growth rate and pubertal development in children with chronic myeloid leukemia treated with imatinib during puberty.Haematologica · 2013
   Article
10. SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation.BMC cancer · 2013
    Article
11. Imatinib inhibits proliferation of human mesenchymal stem cells and promotes early but not late osteoblast differentiation in vitro.Journal of bone and mineral metabolism · 2012
    Article
12. The tyrosine kinase inhibitor dasatinib induces a marked adipogenic differentiation of human multipotent mesenchymal stromal cells.PloS one · 2011
    Article
13. Endocrine side effects of broad-acting kinase inhibitors.Endocrine-related cancer · 2010
    Review
14. Second-generation TKI dasatinib inhibits proliferation of mesenchymal stem cells and osteoblast differentiation in vitro.Leukemia · 2010
    Article
15. The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblasts.BMC cancer · 2010
    Article
16. Impact of the type of the BCR-ABL fusion transcript on the molecular response in pediatric patients with chronic myeloid leukemia.Haematologica · 2010
    Article
17. Longitudinal growth retardation in a prepuberal girl with chronic myeloid leukemia on long-term treatment with imatinib.Haematologica · 2009
    Article

Corrections and comments

• Commented on by
  Longitudinal growth retardation in a prepuberal girl with chronic myeloid leukemia on long-term treatment with imatinib.2009

Authors and funding

6 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as